An Thought Leaders Invited Review published today in Genomic Psychiatry by Dr. Peng Lei and colleagues presents a sweeping ...
Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do ...
Thank you guys for being here. Super excited to have Biogen management join Alisha. Thank you for making time. I'll let you kick things off. Thank you. Thank you for all of you that showed up today. I ...
Novo Nordisk’s Rybelsus (oral semaglutide) has failed to demonstrate efficacy in a late-stage trial in Alzheimer’s disease, denting hopes of glucagon-like peptide-1 receptor agonists (GLP-1RAs) ...
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued ...
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback